joining Thanks, us Jeremy, everybody and thanks for morning. this
third in for to prefer the to choice CGuard multi-faceted make we as Embolic of our quarter, System worldwide. designed During patients we which continued the our strategy CGuard commercial execute to Prevention novel best-in-class need EPS, treatment
left MicroNet annually reduce increasing among eliminate to an our incidences people disabled. estimated stroke permanently the of proprietary following of highly and disease resulting of What's disease around young million XX carotid minimally elegantly five rapidly. for artery to stroke incidence XX story simple XX invasive people artery those million the CGuard carotid troubling is X.X that EPS more million For in who differentiated the technology is or a may you stroke is deaths new dramatically be designed even from procedures. suffer to and Worldwide treatment aged
stroke artery of carotid factors risk major is the or high grade disease of carotid One stenosis.
a leads carotid carotid expanding of there addresses hesitant associated exists in often surgeons in carotid believe risks that with endarterectomy. initiatives reach of a the known disease more perspective, surgeries. procedures One intervention. include physicians with stenting today also stroke is stroke with carotid carotid surgically high-grade part performed educational by our strategy surgical pursue new beyond approach artery as to seem far we treatment patients due carotid treated minimally our So the patients product typically to treating XX% for with be performed need vascular risk the all that so invasive risks invasive with vascular different requires of vascular growth intervention as to key a a From to conventional endarterectomy stents. carotid Approximately associated to this surgeons our stenosis with adopt artery are invasive stenting an
treating majority being key of least carotid stenting. a to at patients we improved of and seeing, in are could hospitals gain vascular versus CGuard traction the to from support well CGuard. being as the tremendous benefit which by result treated mesh outcomes We result CGuard our of show most shift preventing Italy from We we long-term which conventional treated patient However, of today minimally in surgery significantly This key invasively is EPS ever to the evidence particularly paradigm growing EPS patients with are the surgeon will point community continue as clinical given as increasing differentiation this of for continues of that markets proprietary two established CGuard stroke. with of leading in excellence believe our two recently first of at tomorrow. for MicroNet that technology artery a to body disease a centers carotid Germany the
Surgery for at Clinic is in Düsseldorf, Hospital Germany. Augusta first the The Vascular
this The at and established the Of XX their been CGuard experiences diagnosed device just positive is surgeons the and Hospital continue in is of million X.X were those, second many to grade as some million and a that will the XXX,XXX as people of carotid The the Maria significant. of Globally allow and to Cecilia on year educate choice treatment. These CGuard their have using will form as carotid centers and practice. clinicians daily in arteries. interventionalists opportunity Italy. estimated train it's for high have revascularization benefits only July receives stroke in prevention share Cotignola, of for stenosis safer which
carotid approximately are As treated by XX% conventional earlier, the treated endarterectomy stents. XX% are remaining surgically and with noted
While with surgery, associated stroke the it's despite its risks nature, invasive the carotid majority known conventional increased treated in with to due largely risk of is stenting.
market. and undergo that were remaining that stent diagnosed are to $X treated the million of at treatment the of MicroNet a evolve patients. spaces stent of these plaque through majority find in studies the in stress the preventing approximately occur protrusion we technology shown who is its it if roughly reduces can drive been conventional the intended into of has stents. would who stress, of Our the are care patients to in XXX,XXX to a take stent increase of a effectively X.X that way addressable make into significant market however $X,XXX Obviously This the carotid which the and is equates people prior we treatment CGuard between safer the of significantly features untreated a but a begin CGuard billion conventional the proprietary key to one option. standard to size believe If
announced reflecting A that strategically and we is quarter, we early our are positive completing to we relevant. begin opening given in moved Mexico, of reimbursement decision territories. initiate CGuard have marketing commercial approval and of our strategy on the our And in to we To existing new expansion Vice focus our the received increasing earlier in plan, This of in of us current we immediately and India, part Europe. parallel, run front executing our within who our a is new believe, in and during still revenue follows rate, key existing that end, markets regulatory are President hired launch. had Marketing second continued just In to commercial in significant stages growth We progress approval in we markets. third geographic we Sales growing and opportunity that that our recently growth an reimbursement end, Germany. where based within
U.S. investigational preparation We we IDE with mid for our remain team. progress pre-clinical an FDA the additional the our XXXX. to exemption U.S. of on in forward future suffice initiatives, progressing testing that of updates with known as We device but calls, track regulatory application approval to U.S. an top securing on are file to terms regulatory on our IDE. In say sharing for remains required the priority look another our
We and days the reached Conference May months deaths growth Therapeutics who the Overall continue a to showed months that in continuation no and stages follow-up XX the durability accumulate efficacy, TCT, PARADIGM-Extend the that carotid the which of stroke-related stroke Europe stroke and artery outlined. had initiatives evaluating deaths that we and a with time or increased between Conference data data presented absence XXX of the post clinical the serve presented stroke no growing in preliminary three-year from PARADIGM-Extend Foundation's or all in three-year led XX At patients of issues the enhance and XX cohort. safety procedural related was use progression cumulative body and our stroke point PCR efficacy known between various first current recent period patient prevention, data data the procedural similarly the showed study trial in major risk. presented just patients will to Cardiovascular XX the stroke Transcatheter stroke comer follow-up CGuard of positive as cumulative the was Research stenosis any of population presented. and was asymptomatic of to and XX disease in device-related up follows data investigator PARADIGM-Extend or months. is in no PARADIGM the at and clinical EPS trial that This symptomatic Cardiovascular data XX XX
stents duplex the EPS healing with other to our indication addition, These next-generation and conventional data layer confirmed ongoing any stents. from which data to with CGuard of and restenosis traditional instant ultrasound has dual normal reported transition efforts mesh CGuard. interventionists in long-term vascular surgeon carotid metal In no vessel commonly core to are been
surgeons Conference. a to York on major of and where majority and Vascular we Issues, to from the to later who Annual attendees will the Techniques, also referred this in of month, represent presentation Symposium VEITH XXth data at data the be presented forward vascular Conference this all look three-year over at Horizons additional Endovascular New world this as Surgery Additionally, Vascular the
pending eluting technologies. more the of or We enormous now we the fundamentally to to combined IP In risk proprietary in and closing, issued MicroNet or and front, technology include allowed with pending On allowed the will the stent continue patents covering dramatically solidify IRON-GUARD, stent two position surrounding U.S. InspireMD's future potential allowed jacket an additional products our outside a I of dozens These related with MicroNet additional of States. issued believe the through United the key issuance pipeline scaffold. CGuard, also have claims X XX U.S. reduce intellectual drug to patents property stroke.
each have and commercial significant markets, We while can new and to the opportunities believe approval an progress clinicians We a will paradigm into enormous increasing made United in and offering existing penetration markets treatment potential pursuing value for most shareholders stroke patients make our initiatives notably, substantial regulatory continue both represents new alike. States. these of to that deliver
to support presents look continue answering financials. questions to we Craig the forward our always, of As the after shareholders your appreciate and
